Phase II Study in Fragile X Syndrome -- IND clearance received from FDA; first patient enrollment targeted by year-end with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results